-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Non-alcoholic steatohepatitis (NASH) is a chronic liver disease with no approved treatment.
Recently, a research article was published in the top medical journal Nature Medicine.
The primary endpoint of the study was the decrease in liver triglycerides found by magnetic resonance spectroscopy at 52 weeks after treatment with 600 mg of Aramchol
600mg Aramchol can obtain a placebo-corrected liver triglyceride reduction, but does not meet the pre-specified significance (-3.
Although the primary endpoint of 600mg Aramchol treatment for reducing liver fat did not reach the pre-specified significance level, the observed safety and liver histology and enzyme changes provide SCD1 regulation as a promising treatment for NASH and fibrosis The basis
Although the primary endpoint of 600mg Aramchol treatment for reducing liver fat did not reach the pre-specified significance level, the observed safety and liver histology and enzyme changes provide SCD1 regulation as a promising treatment for NASH and fibrosis The basis
Original source:
V.
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
in this message
